GlassScriptPhysician profile
David J Headen
NPI 1528160348
$8,346.61
in general payments reported to CMS, 2019-2025
50 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $1,063 · 2021: $941 · 2022: $1,081 · 2023: $1,431 · 2024: $1,552 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,256 · Education: $8.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,255.54 |
| Education | $8.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $935.97 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $780.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $683.19 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $631.26 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $566.30 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $441.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $370.21 | 2019-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $357.11 | 2021-2025 | |
| Pfizer INC. | $354.40 | 2019-2025 | |
| Abbott Laboratories | $318.87 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.74 | 2019-2024 | Ofev, Tradjenta, Jardiance |
| Teva Pharmaceuticals USA, INC. | $254.63 | 2019-2023 | Airduo Digihaler |
| E.R. Squibb & Sons, L.L.C. | $210.55 | 2020-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $198.93 | 2020-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Amarin Pharma, INC. | $192.20 | 2019-2020 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Headen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.